Molly Harper Biography and Net Worth



Molly Harper has over 20 years of experience focusing on commercial strategy and leadership at life sciences companies of all sizes. Since October 2021, Ms. Harper has served as Chief Business Officer for Synlogic, Inc. a clinical-stage biotechnology company bringing the transformative potential of synthetic biology to medicine. Ms. Harper joined Synlogic from Relmada Therapeutics, Inc., where she was most recently Executive Vice President of Operations. Prior to Relmada she served in positions of increasing responsibility with Akcea Therapeutics, including most recently as Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the commercialization of two rare disease drugs. Ms. Harper was also Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme, having previously served at various positions in sales and marketing with Merck & Co, equity research at UBS Warburg and strategy consulting at The Wilkerson Group/IBM.

Ms. Harper received her Bachelor of Arts from Cornell University and her Master of Business Administration from The Wharton School of the University of Pennsylvania. Ms. Harper also serves on the Board of Directors of PreciseDx, a privately held AI oncology pathology company.

How do I contact Molly Harper?

The corporate mailing address for Ms. Harper and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Molly Harper's contact information.

Has Molly Harper been buying or selling shares of Catalyst Pharmaceuticals?

During the past quarter, Molly Harper has sold $385,000.00 of Catalyst Pharmaceuticals stock. Most recently, Molly Harper sold 17,500 shares of the business's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a transaction totalling $385,000.00. Learn More on Molly Harper's trading history.

Who are Catalyst Pharmaceuticals' active insiders?

Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Catalyst Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 550,755 shares worth more than $9,844,488.44. The most recent insider tranaction occured on December, 10th when insider Steve Miller sold 50,000 shares worth more than $1,096,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.

Information on this page was last updated on 12/10/2024.

Molly Harper Insider Trading History at Catalyst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/27/2024Sell17,500$22.00$385,000.00View SEC Filing Icon  
6/3/2024Sell5,333$16.30$86,927.90View SEC Filing Icon  
See Full Table

Molly Harper Buying and Selling Activity at Catalyst Pharmaceuticals

This chart shows Molly Harper's buying and selling at Catalyst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Read More

Today's Range

Now: $21.97
Low: $21.58
High: $22.11

50 Day Range

MA: $21.52
Low: $19.73
High: $23.93

2 Week Range

Now: $21.97
Low: $13.00
High: $24.27

Volume

660,713 shs

Average Volume

1,172,869 shs

Market Capitalization

$2.62 billion

P/E Ratio

18.62

Dividend Yield

N/A

Beta

0.75